Pronai Therapeutics reports positive results from PNT2258 Phase II study on lymphoma

ProNAi Therapeutics, Inc., a leader in developing nucleic acid therapeutics, presented safety and efficacy data from its ongoing Phase II study yesterday at the 55th Annual Meeting of the American Society for Hematology (ASH) in New Orleans, Louisiana. Phase II findings on the company's first-in-class BCL2 targeted IV drug were presented in an oral session on Novel Therapies for Lymphoma, titled "The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin's Lymphoma." PNT2258's unique mechanism of action targets the BCL2 gene directly, rather than the BCL2 protein, to inhibit cancer cell proliferation, drive cell death (apoptosis) and minimize off-target effects. 

"PNT2258 is a promising novel approach to treating lymphoma, and cancer therapy in general. This is exciting and offers hope to our patients whose tumors have failed to respond to other therapies. It was a pleasure to share the results with so many of my colleagues at ASH," stated principal investigator Dr. Ayad Al-Katib, MD, FACP, Director of St. John Providence Hospital and Medical Center's, Van Elslander Cancer Center in Detroit, Michigan.

PNT2258 Phase II Data Presented at ASH on December 8, 2013 (Abstract #88):

  • PNT2258, a first-in-class BCL2 targeted drug, exhibits single agent anti-tumor activity in patients with recurrent or refractory NHL.
  • 82% of patients had tumor shrinkage when receiving single-agent therapy with PNT2258. To date, overall response rate in patients with follicular lymphoma (FL) is 40% and in patients with diffuse large B-cell lymphoma (DLBCL) is 50%.
  • Several patients have elected to receive additional maintenance therapy after their planned 6 treatment cycles.
  • PNT2258 is safe at a dose of 120 mg/m2 IV administered for 2-3 hours on days 1-5 of a 21-day schedule. No tumor lysis syndrome or major organ toxicities were observed. No occurrences of elevated liver enzymes, hyperkalemia, hyperphosphatemia, hypocalcemia, renal failure/dysfunction, or infections were noted. Additionally, no Grade 4 toxicities.
  • PNT2258 drug exposures levels (AUC) exceeded by at least four-fold that required for anti-tumor activity in xenograft studies of human tumors, consistent with the Phase I study.
  • Preliminary pharmacodynamic markers demonstrated on-target BCL2 activity, including lymphocyte and platelet effects.
  • With the promising results in DLBCL and FL patients, additional PNT2258 single-agent and combination studies are planned.

"Patient with symptomatic disease experienced significant improvement in quality of life as their disease responded to treatment. Infusions were very well tolerated without any significant immediate or cumulative toxicities. The complete responses and durability of responses observed to date suggest that PNT2258 may become a valuable new therapy for NHL patients who have very limited treatment options," commented study investigator Dr. Wael Harb, MD, Horizon Oncology Research, Lafayette, Indiana.

"These results reinforce our enthusiasm for PNT2258 and its potential to treat hematologic tumors," said Mina Sooch, CEO of ProNAi. "In particular, the data presented at ASH are the first to show systemic, clinical activity by a DNAi drug. We look forward to expanding the current trial and initiating new studies in NHL patients in 2014. In addition, our first peer-reviewed publication has just been accepted this December in Cancer Chemotherapy and Pharmacology titled: A Phase 1 study of the BCL2 targeted deoxyribonucleic acid inhibitor PNT2258 in patients with advanced solid tumors. 2013 was a milestone year for ProNAi as we clinically validated our DNAi drug delivery platform and advanced a new BCL2 targeted drug candidate with potential synergies to current and many new lymphoma therapies."

Source:

ProNAi Therapeutics

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Yale study identifies racial and ethnic disparities in Oncotype DX testing for women with breast cancer